Cargando…

Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab

INTRODUCTION: Interleukin (IL)-6 is a proinflammatory cytokine involved in systemic juvenile idiopathic arthritis (SJIA). Since these patients are often treated with tocilizumab (TCZ), anti-IL-6 receptor (IL-6R) antibody, we investigated correlations between serum IL-6 and soluble IL-6R-levels and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vilaiyuk, Soamarat, Lerkvaleekul, Butsabong, Soponkanaporn, Sirisucha, Setthaudom, Chavachol, Buranapraditkun, Supranee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Polish Society of Experimental and Clinical Immunology 2019
Materias:	Clinical Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745541/ https://www.ncbi.nlm.nih.gov/pubmed/31530985 http://dx.doi.org/10.5114/ceji.2019.87066

Ejemplares similares

The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2014)

The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Vilaiyuk, Soamarat, et al.
Publicado: (2018)

Assessment of transition readiness in adolescents in Thailand with rheumatic diseases: a cross-sectional study
por: Kittivisuit, Sirinthip, et al.
Publicado: (2021)

Central nervous system involvement and thrombocytopenia as predictors of mortality in children with hemophagocytic lymphohistiocytosis
por: Harnchoowong, Saralee, et al.
Publicado: (2022)

Effect of educational brochure compared with video on disease-related knowledge in patients with juvenile idiopathic arthritis: A randomized controlled trial
por: Sunthornsup, Waraporn, et al.
Publicado: (2022)

Long-term growth and final adult height outcome in childhood-onset systemic lupus erythematosus
por: Ponin, Lalita, et al.
Publicado: (2022)

Macrophage activation syndrome: early diagnosis is key
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2018)

Factors associated with medication adherence among children with rheumatic diseases
por: Manatpreeprem, Roongroj, et al.
Publicado: (2023)

Associations of lymphocyte subpopulations with clinical phenotypes and long-term outcomes in juvenile-onset systemic lupus erythematosus
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2022)

Evaluating performance of the 2019 EULAR/ACR, 2012 SLICC, and 1997 ACR criteria for classifying adult-onset and childhood-onset systemic lupus erythematosus: A systematic review and meta-analysis
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2022)

PReS-FINAL-2104: Disease course and predictors of outcome in systemic onset juvenile idiopathic arthritis
por: Soponkanaporn, S, et al.
Publicado: (2013)

Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2019)

Age‐related changes in lymphocyte subpopulations in healthy Thai children
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2019)

Outcomes in children with rheumatic diseases following COVID-19 vaccination and infection: data from a large two-center cohort study in Thailand
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2023)

Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
por: Kumar, Abhishek, et al.
Publicado: (2022)

Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review
por: Chantarogh, Songkiat, et al.
Publicado: (2017)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
por: Kittiratchakool, Nitichen, et al.
Publicado: (2020)

The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus
por: Thanadetsuntorn, Chokchai, et al.
Publicado: (2018)

Glucose metabolism in systemic juvenile idiopathic arthritis
por: Suppasit, Papatsorn, et al.
Publicado: (2022)

Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
por: Reiff, Andreas
Publicado: (2012)

Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
por: Yanagida, Mitsuaki, et al.
Publicado: (2013)

Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis
por: Hoffman, Elinoar, et al.
Publicado: (2019)

Interleukin-6 overproduction correlates with disease activity and severity in juvenile idiopathic arthritis
por: Spirchez, Mihaela, et al.
Publicado: (2011)

Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL
por: Chatzidionysiou, Katerina, et al.
Publicado: (2021)

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
por: Yokota, S, et al.
Publicado: (2013)

Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis
por: De La Torre, Miguel, et al.
Publicado: (2011)

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
por: Patel, Aarat M, et al.
Publicado: (2010)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells
por: Lokau, Juliane, et al.
Publicado: (2020)

High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder
por: Lu, Yun-Rong, et al.
Publicado: (2019)

Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study
por: Kohsari, Maryam, et al.
Publicado: (2020)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis
por: Isaacs, John D, et al.
Publicado: (2013)

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
por: Mihara, Masahiko, et al.
Publicado: (2011)

Serum levels of interleukin-6 are not dependent on the kidney function
por: Nässberger, L.
Publicado: (1992)

Serum levels of interleukin 6 in patients with lung cancer.
por: Yanagawa, H., et al.
Publicado: (1995)

Serum levels of interleukin-6 and interleukin-8 as diagnostic markers of acute pyelonephritis in children
por: Mahyar, Abolfazl, et al.
Publicado: (2013)

Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients
por: Othman, Mohamed S., et al.
Publicado: (2013)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ulpluttbjbt9tjc0v0jisv1t7n